Is the Paradigm for Bifurcation Lesions Changing Once More?

Four years ago, we published a summary of the SMART-STRATEGY Study saying that, with bifurcation lesions, “less is more.”

La era del stent provisional para las bifurcaciones parece llegar a su fin

Last month, the DEFINITION Study published in the European Heart Journal suggested that things were about to change. Today, the DK-crush technique seems to have rendered both title and article obsolete.

According to this recent analysis published in J Am Coll Cardiol Intv, we should change the paradigm for bifurcation lesions to “more is more.”

The double-kissing and double-crush (DK-crush) technique was linked to fewer events driven by lower rates of revascularization. However, the rates of incidence for death, myocardial infraction, and stent thrombosis were similar to those observed with provisional stenting.

The clinical benefit of the 2-stent technique over provisional stenting was observed in bifurcation lesions with side branch lesion lengths of over 10 mm.


Read also: Two-Stent Strategy is Safer in True Bifurcation Lesions.


A total of 5711 patients from 21 randomized studies using 5 different techniques to treat bifurcation lesions (provisional stenting, T stenting, crush, culotte, and DK-crush) were analyzed. The mean follow-up was 12 months (9 to 36 months).

When considering all techniques, patients treated using the DK-crush technique had less events (odds ratio [OR]: 0.39; 95% confidence interval [CI]: 0.26 to 0.55) compared with those treated with provisional stenting.

This event reduction with DK-crush was primarily driven by lower rates of target lesion revascularization.


Read also: The Era of Provisional Stenting for Bifurcations Comes to an End.


No significant differences among techniques were observed in hard endpoints, such as cardiac death, myocardial infarction, and stent thrombosis.

Omitting DK-crush, all techniques had similar comparative results.

Original Title: Clinical Outcomes Following Coronary Bifurcation PCI Techniques. A Systematic Review and Network Meta-Analysis Comprising 5,711 Patients.

Reference: Giuseppe Di Gioia et al. J Am Coll Cardiol Intv 2020;13:1432–44. https://doi.org/10.1016/j.jcin.2020.03.054.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

1-Year Outcomes of US TAVR Registry with 5th Generation Balloon Expandable Valves

The use of transcatheter aortic valve replacement (TAVR) has extended to younger patients with lower risk severe aortic stenosis (AS) and therefore the improvement...

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...